Intero Biosystems wants drugmakers to test on mini human intestines, not animals

The Bio-Infrastructure Gap

In the tech world, we talk a lot about 'testing in production.' In the pharmaceutical world, testing in production means putting a chemical into a living creature and hoping it doesn't die. For decades, the industry standard has been animal models. We use mice, rats, and monkeys because they are biological proxies for humans. But as any founder who has tried to port code from one environment to another knows, proxies are often buggy. A drug that works in a mouse often fails in a human because the biological operating systems aren't compatible.

Intero Biosystems is trying to fix this by building what I call 'bio-infrastructure.' They aren't just growing cells; they are manufacturing miniature, functional human intestines—organoids—that allow drugmakers to test treatments on actual human biology without the ethical and scientific baggage of animal testing. This isn't just a win for animal rights activists; it’s a massive shift in how we build and validate biological products.

Moving Past the Mouse Model

The problem with animal testing isn't just the ethics, though that is a significant hurdle for modern companies. The real problem is efficiency. The failure rate for new drugs entering human trials is staggering, often cited around 90%. Much of that failure happens because animals are simply bad at predicting human toxicological responses. If you’re a builder in the biotech space, you’re essentially gambling millions of dollars on a platform—the animal body—that doesn't match your target deployment environment.

Intero’s approach leverages the fact that we can now grow complex, 3D tissue structures that mimic the architecture of human organs. Their focus on the intestine is strategic. The gut is where drugs are absorbed, where the immune system does much of its heavy lifting, and where the microbiome lives. If you can simulate how a drug interacts with a human gut in a lab dish, you bypass the 'lost in translation' phase of animal trials.

The Regulatory Tailwinds

Smart founders look for regulatory shifts that create new markets. We saw it with GDPR in data privacy and we’re seeing it now in life sciences. Regulators are finally signaling that animal testing is no longer the gold standard. In the U.S., the FDA Modernization Act 2.0 has opened the door for alternative testing methods, including organoids and 'organ-on-a-chip' technology.

Intero is positioning itself at the center of this transition. By selling these lab-grown intestines to drugmakers, they are providing a standardized, scalable product for a market that is desperate to reduce the cost and time of drug discovery. In the old model, you had to breed, house, and eventually dispose of animals. In the new model, you order a batch of human organoids that are genetically consistent and highly predictable. It’s moving biology toward a manufacturing mindset.

Scalability is the Real Challenge

If you've spent any time around biotech, you know that growing things is easy; scaling things is hard. A researcher can grow a few organoids in a Petri dish for a PhD thesis. But providing thousands of identical, high-quality organoids to a global pharmaceutical giant like Pfizer or Novartis is a logistics and engineering nightmare. Biology is messy, sensitive to temperature, and prone to contamination.

This is where Intero’s founder-perspective matters. They aren't just selling a scientific discovery; they are building a production line. To replace animal testing, these mini-organs need to be as reliable as a server rack. If one batch of intestines reacts differently than the next due to manufacturing variance, the data becomes useless. The real innovation here isn't just the organoid itself—it’s the process of industrializing the growth of human tissue.

Why Builders Should Care

You might be wondering what a startup growing guts has to do with AI or crypto. The answer is data quality. We are currently in an era where AI is being used to design new proteins and drug molecules. But AI is only as good as its training data. If we feed AI data from flawed animal studies, we get flawed drug designs.

By using human organoids, we generate high-fidelity biological data that can be fed back into machine learning models. This creates a feedback loop: AI designs the drug, organoids test the drug, and the results refine the AI. This is the 'closed-loop' development cycle that will define the next decade of biotechnology. For builders, the takeaway is clear: the most valuable infrastructure isn't just the code, it's the interface between the digital and the biological.

The Skeptic's Corner

It’s worth noting that we aren't at the 'Matrix' level of organ replacement yet. A mini-intestine in a lab lacks a full circulatory system, a brain, and a complete immune system. It’s a localized simulation, not a full-system test. There will still be cases where a drug seems safe in an organoid but causes issues in a whole human body.

However, the goal isn't perfection; it’s improvement over the status quo. If Intero can help a drug company kill a failing project six months earlier by showing toxicity in a human organoid, they save that company tens of millions of dollars. That’s a value proposition that sells itself regardless of whether animal testing is fully abolished tomorrow.

Takeaway for Founders

Stop looking at biotech as a separate silo. The same principles of standardization, scalability, and data integrity that apply to software apply here. Intero Biosystems is treating human biology as a platform for testing. If you can find a way to provide high-fidelity, standardized data in a messy industry, you don't just have a product; you have the new industry standard.

Read the original at TechCrunch Startups →